TG Therapeutics, Inc. (TGTX)
Largest Insider Buys in Sector
TGTX Stock Price History Chart
TGTX Stock Performance
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone …
Insider Activity of TG Therapeutics, Inc.
Over the last 12 months, insiders at TG Therapeutics, Inc. have bought $0 and sold $3.4M worth of TG Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at TG Therapeutics, Inc. have bought $1.11M and sold $2.97M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 100,000 shares for transaction amount of $1.01M was made by WEISS MICHAEL S (CEO and President) on 2023‑08‑11.
List of Insider Buy and Sell Transactions, TG Therapeutics, Inc.
| 2024-11-11 | Sale | director | 25,000 0.0157% | $30.20 | $754,875 | +1.33% | ||
| 2024-11-11 | Sale | director | 5,000 0.0032% | $30.44 | $152,200 | +1.33% | ||
| 2024-11-05 | Sale | director | 20,000 0.0131% | $24.48 | $489,600 | +1.34% | ||
| 2024-06-20 | Sale | director | 16,348 0.011% | $16.87 | $275,791 | +37.28% | ||
| 2024-06-17 | Sale | director | 9,585 0.0063% | $16.39 | $157,098 | +40.31% | ||
| 2024-03-13 | Sale | director | 5,000 0.0033% | $15.94 | $79,675 | +16.96% | ||
| 2024-03-12 | Sale | director | 22,000 0.0144% | $15.97 | $351,340 | +14.84% | ||
| 2024-01-05 | Sale | director | 17,500 0.0112% | $19.03 | $333,025 | -13.43% | ||
| 2024-01-03 | Sale | CFO | 47,867 0.0318% | $16.91 | $809,431 | +0.77% | ||
| 2023-08-11 | CEO and President | 100,000 0.0669% | $10.13 | $1.01M | +49.16% | |||
| 2023-06-23 | Sale | director | 34,854 0.0246% | $23.37 | $814,538 | -36.10% | ||
| 2023-06-02 | Sale | Chief Financial Officer | 73,647 0.0528% | $26.70 | $1.97M | -43.22% | ||
| 2023-01-06 | director | 9,000 0.0063% | $10.64 | $95,760 | +44.54% | |||
| 2023-01-04 | Sale | director | 30,000 0.0221% | $11.10 | $333,000 | +43.66% | ||
| 2022-01-05 | Sale | CEO and President | 30,671 0.0239% | $18.31 | $561,586 | -57.97% | ||
| 2022-01-05 | Sale | CFO, Secretary and Treasurer | 9,653 0.0075% | $18.31 | $176,746 | -57.97% | ||
| 2022-01-04 | Sale | CEO and President | 37,549 0.0281% | $19.20 | $720,941 | -61.45% | ||
| 2022-01-04 | Sale | CFO, Secretary and Treasurer | 75,312 0.0564% | $19.20 | $1.45M | -61.45% | ||
| 2020-12-10 | Sale | director | 30,000 0.025% | $40.05 | $1.2M | -10.03% | ||
| 2020-09-09 | Sale | 10 percent owner | 158,589 0.1337% | $25.81 | $4.09M | +46.17% |
Insider Historical Profitability
| Power Sean A | CFO | 606969 0.3899% | $34.76 | 2 | 21 | |
| Echelard Yann | director | 224098 0.144% | $34.76 | 1 | 2 | +44.54% |
| WEISS MICHAEL S | CEO and President | 12073021 7.7558% | $34.76 | 6 | 3 | +76.33% |
| LFB Biotechnologies S.A.S.U. | 10 percent owner | 5114855 3.2858% | $34.76 | 1 | 0 | +3.39% |
| ROSENWALD LINDSAY A MD | 10 percent owner | 2649321 1.7019% | $34.76 | 59 | 0 |
Institutional Investor Ownership
| The Vanguard Group | $205.9M | 8.76 | 13.54M | -0.98% | -$2.04M | <0.01 | |
| BlackRock | $164.93M | 7.02 | 10.84M | +0.7% | +$1.15M | <0.01 | |
| State Street | $118.59M | 5.05 | 7.8M | -5.54% | -$6.95M | 0.01 | |
| Millennium Management LLC | $52.99M | 2.25 | 3.48M | +18.96% | +$8.45M | 0.03 | |
| Soleus Capital Management, L.P. | $48.19M | 2.05 | 3.17M | +387.45% | +$38.31M | 0.2 |